Research suggests benefits in mild-to-moderate depression, but medication interactions limit its role for many patients. Lower-dose formulations may reduce risk.
While the full details of the agreement have not been publicly released yet, the group describes the agreement as a ‘a significant investment in physicians and healthcare’ and a ‘strong step forward for B.C. doctors and patients.’